Head to head
Semaglutide against Empagliflozin
Two drug classes people with type 2 diabetes are commonly choosing between, and one of the few pairs on this site where the choice has been randomised directly. Both have cardiovascular outcome data of their own; the trial below measured neither.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
EmpagliflozinEmpagliflozin (sodium-glucose cotransporter 2 inhibitor)
Four randomised outcome trials in more than 23,000 people, including a 32 percent relative reduction in all-cause death in EMPA-REG OUTCOME. The entire ageing case is one single-laboratory mouse study reporting 5.9 percent longer median survival in males, and the Interventions Testing Program has never tested this drug.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
HbA1c fell 1.3 percent on oral semaglutide against 0.9 percent on empagliflozin at week 26 under the treatment policy estimand, an estimated treatment difference of 0.4 percentage points (95% CI 0.6 to 0.3, p < 0.0001). Superior weight loss was not confirmed at week 26; at week 52 weight fell 4.7 kg against 3.8 kg on the trial product estimand (p = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide.
What the trial was
52 week, randomised, open-label trial. 822 adults with type 2 diabetes uncontrolled on metformin were randomised to once-daily oral semaglutide 14 mg (412) or empagliflozin 25 mg (410). Key endpoints were change in HbA1c at week 26, the primary, and body weight as a confirmatory secondary, each analysed under a treatment policy and a trial product estimand.
What the authors concluded
The authors conclude that oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks, with both reduced significantly at week 52 on the trial product estimand.
Where this result is weak
Open-label, one year, and biomarker endpoints. The weight result did not reach its confirmatory bar at the primary timepoint, which is easy to lose when the 52 week figure is quoted alone. It tested the oral formulation of semaglutide, not the injection, and it was funded by Novo Nordisk. Empagliflozin's main claim is cardiovascular and kidney outcomes over years, and this trial measured none of that.
Side by side, on the facts we can check
| Attribute | Semaglutide | Empagliflozin |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan. |
| Half-life | ~7 days | About 12 hours. |
| Molecular weight | 4,113.6 Da | 450.9 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Selectively inhibits sodium-glucose cotransporter 2 in the proximal tubule, so filtered glucose is excreted rather than reabsorbed. The cardiorenal benefit is larger and faster than glucose lowering alone explains and is not fully accounted for. Candidate contributions include reduced plasma volume and preload, restored tubuloglomerular feedback and lower intraglomerular pressure, a shift toward ketone utilisation by the myocardium, and reduced cardiac sodium-hydrogen exchange. The mouse healthspan work adds AMPK and SIRT1 signalling, short-chain fatty acid production and gut microbial composition to that list, which is a different level of evidence from the outcome trials. |
| Human studies cited | 5 | 4 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Semaglutide and Empagliflozin?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Empagliflozin: Four randomised outcome trials in more than 23,000 people, including a 32 percent relative reduction in all-cause death in EMPA-REG OUTCOME. The entire ageing case is one single-laboratory mouse study reporting 5.9 percent longer median survival in males, and the Interventions Testing Program has never tested this drug.
Which has stronger research evidence, Semaglutide or Empagliflozin?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 4 of 6 for Empagliflozin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Empagliflozin FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Empagliflozin: FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan..
Related posts
Blog articles that cover Semaglutide or Empagliflozin, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.